Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA damage-binding protein 1 (DDB1) is a highly conserved, large (127 kDa) protein that forms a core component of the CUL4-DDB1 E3 ubiquitin ligase complex and is essential for several DNA repair pathways, most notably nucleotide excision repair, where it forms a heterodimer with DDB2 to recognize UV-induced DNA lesions[1][2][4][7][8]. DDB1 serves as an adaptor or scaffold, bridging substrate receptors and the cullin core, thereby facilitating ubiquitination and turnover of numerous protein substrates involved in DNA repair, replication, chromatin remodeling, and cell cycle control[1][2][3][4]. Mutations in the DDB1 complex underlie the rare skin cancer syndrome xeroderma pigmentosum group E, and DDB1 is exploited by certain viruses (e.g., paramyxoviruses, HBV) to degrade host restriction factors[3][4]. While DDB1 has not been therapeutically targeted directly, its central role in maintaining genome stability makes it of high research and translational interest[2][4].
For drug discovery, potential mechanisms may include modulation of DNA repair or CUL4-DDB1 ubiquitin E3 ligase activity, but no clinical agents are established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA damage-binding protein 1 (DDB1).